Provided by Tiger Fintech (Singapore) Pte. Ltd.

CRISPR Therapeutics AG

52.17
+0.50000.97%
Post-market: 52.170.00000.00%16:58 EDT
Volume:1.84M
Turnover:95.50M
Market Cap:4.51B
PE:-11.55
High:53.08
Open:52.36
Low:51.15
Close:51.67
Loading ...

Crispr Therapeutics to Partner With Sirius Therapeutics to Develop siRNA Therapies

Dow Jones
·
20 May

CRISPR Therapeutics AG Announces Collaboration with Sirius Therapeutics to Develop Next-Gen siRNA Therapy Targeting Thrombosis

Reuters
·
20 May

Crispr Therapeutics, Sirius Therapeutics to commercialize siRNA therapies

TIPRANKS
·
20 May

Here's the most unappreciated AI beneficiary right now, according to Ark Invest's Cathie Wood

Dow Jones
·
19 May

Prediction: This Beaten-Down Stock Could Double in The Next 5 Years

Motley Fool
·
18 May

Bank of America Securities Sticks to Its Buy Rating for Crispr Therapeutics AG (CRSP)

TIPRANKS
·
16 May

Stock Track | CRISPR Therapeutics Soars 5% on Casgevy Sales and Strong Pipeline Prospects

Stock Track
·
16 May

Are Investors Making a Big Mistake Dumping Shares of CRISPR Therapeutics?

Motley Fool
·
14 May

Cathie Wood Dumps Palantir As Stock Touches Peak Prices, Bails On Soaring Flying-Taxi Maker Archer Aviation

Benzinga
·
14 May

2 Biotech Stocks That Are Screaming Buys in May

Motley Fool
·
13 May

Stock Track | CRISPR Therapeutics Soars 5% on Casgevy Sales and Strong Pipeline Prospects

Stock Track
·
13 May

Stock Track | CRISPR Therapeutics Soars 5% on Casgevy Sales and Strong Pipeline Prospects

Stock Track
·
13 May

Stock Track | CRISPR Therapeutics Soars Nearly 6% Pre-market on Casgevy Sales and Strong Pipeline Prospects

Stock Track
·
12 May

Stock Track | CRISPR Therapeutics Soars 5.56% in Pre-market on Commercialization Progress and Strong Pipeline

Stock Track
·
12 May

Stock Track | CRISPR Therapeutics Soars 5.56% Pre-market on Commercialization Progress and Growth Potential

Stock Track
·
12 May

Can Buying CRISPR Therapeutics and Holding It Forever Make You a Millionaire?

Motley Fool
·
12 May

3 Monster Stocks to Hold for the Next 10 Years

Motley Fool
·
10 May

Intellia Therapeutics: Promising CRISPR-Based Therapies Drive Buy Rating Amid Clinical Advancements

TIPRANKS
·
09 May

Stock Track | CRISPR Therapeutics Soars 5.05% as Cathie Wood's Ark Invest Adds to Position

Stock Track
·
08 May

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Motley Fool
·
08 May